Sensei BiotherapeuticsSNSE
Market Cap: $12.3M
About: Sensei Biotherapeutics Inc is an immuno-oncology company focused on the discovery and development of next-generation therapeutics for cancer patients. Its TMAb (Tumor Microenvironment Activated Biologics) platform developing highly selective therapeutics designed to disable immunosuppressive signals or activate immunostimulatory signals selectively in the tumor microenvironment. The company have four investigational product candidates in various stages of development: SNS-101, SNS-102, SNS-103, SNS-20.
Employees: 28
Fund manager confidence
Based on 2024 Q2 SEC filings by fund managers ($100M+ AUM)
0% more repeat investments, than reductions
Existing positions increased: 6 | Existing positions reduced: 6
0.86% less ownership
Funds ownership: 9.26% [Q1] → 8.4% (-0.86%) [Q2]
4% less funds holding
Funds holding: 25 [Q1] → 24 (-1) [Q2]
17% less first-time investments, than exits
New positions opened: 5 | Existing positions closed: 6
46% less capital invested
Capital invested by funds: $2.44M [Q1] → $1.31M (-$1.13M) [Q2]
Research analyst outlook
1 Wall Street Analyst provided 1 year price targets over the past 3 months
1 analyst rating
HC Wainwright & Co. Edward White 27% 1-year accuracy 33 / 121 met price target | 716%upside $4 | Buy Reiterated | 7 Aug 2024 |